Listen

Add to my selection

TAGRISSO

Medicine - Posted on May 30 2022

Active substance (DCI)

osimertinib

history (4)

1/19/22

TAGRISSO (osimertinib) - Cancer bronchique non à petites cellules (CBNPC)

Key points Favourable opinion for reimbursement only in the adjuvant treatment after complete tumour resection and after adj...

CAV :
54321

icône flèche
3/20/20

TAGRISSO (osimertinib)

Key points Favourable opinion for reimbursement as monotherapy in the first-line treatment of adult patients with locally ad...

CAV :
54321

icône flèche
9/13/17

TAGRISSO (osimertinib), tyrosine kinase inhibitor

Substantial actual benefit and minor improvement compared with chemotherapy combining a platinum salt with pemetrexed in pat...

CAV :
54321

icône flèche
9/21/16

TAGRISSO (osimertinib), tyrosine kinase inhibitor

No clinical benefit demonstrated in the treatment of locally-advanced or metastatic non-small cell lung cancer with EGFR T79...

CAV :
54321

icône flèche

Technical information

ATC code

L01EB04

Manufacturer

ASTRAZENECA

Presentation

TAGRISSO 40 mg, comprimés pelliculés
30 plaquettes aluminium de 1 comprimé - (Code CIP : 34009 300 476 4 4)

TAGRISSO 80 mg, comprimés pelliculés
30 plaquettes aluminium de 1 comprimé - (Code CIP : 34009 300 476 5 1)

All our publications

Health economics

Respiratory tract cancers